Related Experiment Videos

HBs Ag and hepatocellular carcinoma associated with cirrhosis.--A retrospective study based on autopsy

Hepato-Gastroenterology
|October 1, 1980
PubMed

Insights

Hepatocellular carcinoma (HCC) associated with cirrhosis shows a more rapid and severe course when Hepatitis B surface antigen (HBs Ag) is present in liver cells. This suggests HBs Ag plays a role in HCC progression.

Area of Science:

  • Hepatology
  • Oncology
  • Virology

Background:

  • Hepatocellular carcinoma (HCC) is a major global health concern, often developing in patients with liver cirrhosis.
  • The role of Hepatitis B virus infection, specifically Hepatitis B surface antigen (HBs Ag), in HCC pathogenesis and progression requires further elucidation.

Purpose of the Study:

  • To investigate the presence of HBs Ag in liver tissue of patients with HCC and cirrhosis.
  • To determine if HBs Ag presence correlates with clinical outcomes and survival rates in HCC patients.

Main Methods:

  • Histologic examination of liver tissue from 33 HCC patients with cirrhosis.
  • Staining with hematoxylin-eosin and orcein to detect HBs Ag in hepatocytes.
  • Review of clinical data and laboratory examinations to assess patient survival.

Main Results:

  • HBs Ag was detected in the cytoplasm of liver cells in 7 out of 33 (21.2%) HCC patients.
  • A significant difference in survival length was observed between HBs Ag-positive and HBs Ag-negative patients.
  • HBs Ag-positive patients exhibited a more rapid and severe disease course.

Conclusions:

  • HBs Ag presence in liver cells is associated with a poorer prognosis in HCC patients with cirrhosis.
  • These findings support the hypothesis that HBs Ag contributes to both the development and accelerated progression of HCC.
  • Further research into targeted therapies against HBs Ag in HCC is warranted.

Related Concept Videos